Join Growin Stock Community!

杏輝1734.TW Overview

TW StockBiotech. & Medical
(No presentation for 1734)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

杏輝（1734）Overall Performance

杏輝（1734）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

杏輝（1734） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

杏輝（1734）Key Information

杏輝（1734）Profile

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. The company was founded in 1977 and is headquartered in Yilan City, Taiwan.

杏輝（1734）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
16.73
Forward PE
16.89
PS Ratio (TTM)
1.73
PB Ratio
1.62
Price-to-FCF
12.01
METRIC
VALUE
vs. INDUSTRY
Gross Margin
42.51%
Net Margin
10.33%
Revenue Growth (YoY)
11.85%
Profit Growth (YoY)
23.83%
3-Year Revenue Growth
6.81%
3-Year Profit Growth
10.03%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
16.73
Forward PE
16.89
PS Ratio (TTM)
1.73
PB Ratio
1.62
Price-to-FCF
12.01
Gross Margin
42.51%
Net Margin
10.33%
Revenue Growth (YoY)
11.85%
Profit Growth (YoY)
23.83%
3-Year Revenue Growth
6.81%
3-Year Profit Growth
10.03%
1734.TW logo

1734

杏輝

30.40D

-0.82%

(-0.01)

  • When is 1734's latest earnings report released?

    The most recent financial report for 杏輝 (1734) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1734's short-term business performance and financial health. For the latest updates on 1734's earnings releases, visit this page regularly.

  • Where does 1734 fall in the P/E River chart?

    According to historical valuation range analysis, 杏輝 (1734)'s current price-to-earnings (P/E) ratio is 14.52, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1734?

    According to the latest financial report, 杏輝 (1734) reported an Operating Profit of 108.87M with an Operating Margin of 12.48% this period, representing a growth of 98.9% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1734's revenue growth?

    In the latest financial report, 杏輝 (1734) announced revenue of 872.73M, with a Year-Over-Year growth rate of 16.44%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1734 have?

    At the end of the period, 杏輝 (1734) held Total Cash and Cash Equivalents of 895.16M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1734 go with three margins increasing?

    In the latest report, 杏輝 (1734) achieved the “three margins increasing” benchmark, with a gross margin of 43.83%%, operating margin of 12.48%%, and net margin of 9.25%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1734's profit trajectory and future growth potential.

  • Is 1734's EPS continuing to grow?

    According to the past four quarterly reports, 杏輝 (1734)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1734?

    杏輝 (1734)'s Free Cash Flow (FCF) for the period is 20.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.56% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.